Table 2.
First immune checkpoint inhibitor treatments.
| Variables | Cardiotoxicity Developed within One Year after ICI Initiation | % | ||||||
|---|---|---|---|---|---|---|---|---|
| Yes (n = 691) |
No (n = 4827) |
p-Value | Total (n = 5518) |
|||||
| n | % | n | % | n | ||||
| First ICI | Class | 0.0038 | ||||||
| Atezolizumab | PD-L1 | 23 | 3.3% | 178 | 3.7% | 201 | 3.6% | |
| Avelumab | PD-L1 | 7 | 1.0% | 22 | 0.5% | 29 | 0.5% | |
| Durvalumab | PD-L1 | 7 | 1.0% | 49 | 1.0% | 56 | 1.0% | |
| Ipilimumab | CTLA-4 | 85 | 12.3% | 385 | 8.0% | 470 | 8.5% | |
| Nivolumab | PD-1 | 196 | 28.4% | 1570 | 32.5% | 1766 | 32.0% | |
| Pembrolizumab | PD-1 | 324 | 46.9% | 2181 | 45.2% | 2505 | 45.4% | |
| Cemiplimab | PD-1 | 1 | 0.1% | 20 | 0.4% | 21 | 0.4% | |
| Combo | Combo | 48 | 6.9% | 422 | 8.7% | 470 | 8.5% | |
| Nivolumab + Ipilimumab | 48 | 6.9% | 420 | 8.7% | 468 | 8.5% | ||
| Pembrolizumab + ipilimumab | 0 | 0.0% | 1 | 0.0% | 1 | 0.02% | ||
| Pembrolizumab + Nivolumab | 0 | 0.0% | 1 | 0.0% | 1 | 0.02% | ||
| 691 | 4827 | |||||||
| Number of different ICIs used (including agents used in combination) | 0.6878 | |||||||
| 1 | 587 | 84.9% | 4043 | 83.8% | 4630 | 83.9% | ||
| 2 | 93 | 13.5% | 692 | 14.3% | 785 | 14.2% | ||
| 3 | 11 | 1.6% | 92 | 1.9% | 103 | 1.9% | ||
ICI: immune checkpoint inhibitor. CTLA-4: Cytotoxic T-lymphocyte associated-antigen-4. PD-1: programmed death receptor-1. PD-L1: programmed death-ligand 1. Combo: combination.